-
Je něco špatně v tomto záznamu ?
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study
GM. Felker, JJV. McMurray, JG. Cleland, CM. O'Connor, JR. Teerlink, AA. Voors, J. Belohlavek, M. Böhm, M. Borentain, H. Bueno, RT. Cole, MM. DeSouza, JA. Ezekowitz, G. Filippatos, NN. Lang, PD. Kessler, FA. Martinez, A. Mebazaa, M. Metra, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem
- MeSH
- akutní nemoc MeSH
- dvojitá slepá metoda MeSH
- funkce levé komory srdeční MeSH
- lidé MeSH
- oxidy dusíku MeSH
- srdeční selhání * farmakoterapie MeSH
- tepový objem MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
OBJECTIVES: The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure (AHF). Secondary objectives were to identify signals of efficacy, including biomarkers, symptoms, and clinical events. BACKGROUND: Nitroxyl (HNO) donors have vasodilator, inotropic and lusitropic effects. Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for acute heart failure (AHF). METHODS: This was a phase IIb, double-blind, randomized, placebo-controlled trial of 48-h treatment with cimlanod compared with placebo in patients with left ventricular ejection fraction ≤40% hospitalized for AHF. In part I, patients were randomized in a 1:1 ratio to escalating doses of cimlanod or matching placebo. In part II, patients were randomized in a 1:1:1 ratio to either of the 2 highest tolerated doses of cimlanod from part I or placebo. The primary endpoint was the rate of clinically relevant hypotension (systolic blood pressure <90 mm Hg or patients became symptomatic). RESULTS: In part I (n = 100), clinically relevant hypotension was more common with cimlanod than placebo (20% vs. 8%; relative risk [RR]: 2.45; 95% confidence interval [CI]: 0.83 to 14.53). In part II (n = 222), the incidence of clinically relevant hypotension was 18% for placebo, 21% for cimlanod 6 μg/kg/min (RR: 1.15; 95% CI: 0.58 to 2.43), and 35% for cimlanod 12 μg/kg/min (RR: 1.9; 95% CI: 1.04 to 3.59). N-terminal pro-B-type natriuretic peptide and bilirubin decreased during infusion of cimlanod treatment compared with placebo, but these differences did not persist after treatment discontinuation. CONCLUSIONS: Cimlanod at a dose of 6 μg/kg/min was reasonably well-tolerated compared with placebo. Cimlanod reduced markers of congestion, but this did not persist beyond the treatment period. (Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure [STANDUP AHF]; NCT03016325).
Bristol Myers Squibb Princeton New Jersey USA
British Heart Foundation Cardiovascular Research Centre University of Glasgow Glasgow United Kingdom
Canadian VIGOUR Centre at the University of Alberta Edmonton Alberta Canada
Cardiology and Intensive Care Unit Nippon Medical School Musashi Kosugi Hospital Kawasaki Japan
Indiana University School of Medicine Indianapolis Indiana USA
Inova Heart and Vascular Institute Falls Church Virginia USA
Instituto DAMIC Cordoba National University Cordoba Argentina
National and Kapodisrian University of Athens School of Medicine Athens Greece
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21026137
- 003
- CZ-PrNML
- 005
- 20211026133159.0
- 007
- ta
- 008
- 211013s2021 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jchf.2020.10.012 $2 doi
- 035 __
- $a (PubMed)33248986
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Felker, G Michael $u Duke University School of Medicine and the Duke Clinical Research Institute, Durham, North Carolina, USA. Electronic address: michael.felker@duke.edu
- 245 10
- $a Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF Study / $c GM. Felker, JJV. McMurray, JG. Cleland, CM. O'Connor, JR. Teerlink, AA. Voors, J. Belohlavek, M. Böhm, M. Borentain, H. Bueno, RT. Cole, MM. DeSouza, JA. Ezekowitz, G. Filippatos, NN. Lang, PD. Kessler, FA. Martinez, A. Mebazaa, M. Metra, A. Mosterd, PS. Pang, P. Ponikowski, N. Sato, D. Seiffert, J. Ye
- 520 9_
- $a OBJECTIVES: The primary objective was to identify well-tolerated doses of cimlanod in patients with acute heart failure (AHF). Secondary objectives were to identify signals of efficacy, including biomarkers, symptoms, and clinical events. BACKGROUND: Nitroxyl (HNO) donors have vasodilator, inotropic and lusitropic effects. Bristol-Myers Squibb-986231 (cimlanod) is an HNO donor being developed for acute heart failure (AHF). METHODS: This was a phase IIb, double-blind, randomized, placebo-controlled trial of 48-h treatment with cimlanod compared with placebo in patients with left ventricular ejection fraction ≤40% hospitalized for AHF. In part I, patients were randomized in a 1:1 ratio to escalating doses of cimlanod or matching placebo. In part II, patients were randomized in a 1:1:1 ratio to either of the 2 highest tolerated doses of cimlanod from part I or placebo. The primary endpoint was the rate of clinically relevant hypotension (systolic blood pressure <90 mm Hg or patients became symptomatic). RESULTS: In part I (n = 100), clinically relevant hypotension was more common with cimlanod than placebo (20% vs. 8%; relative risk [RR]: 2.45; 95% confidence interval [CI]: 0.83 to 14.53). In part II (n = 222), the incidence of clinically relevant hypotension was 18% for placebo, 21% for cimlanod 6 μg/kg/min (RR: 1.15; 95% CI: 0.58 to 2.43), and 35% for cimlanod 12 μg/kg/min (RR: 1.9; 95% CI: 1.04 to 3.59). N-terminal pro-B-type natriuretic peptide and bilirubin decreased during infusion of cimlanod treatment compared with placebo, but these differences did not persist after treatment discontinuation. CONCLUSIONS: Cimlanod at a dose of 6 μg/kg/min was reasonably well-tolerated compared with placebo. Cimlanod reduced markers of congestion, but this did not persist beyond the treatment period. (Evaluate the Safety and Efficacy of 48-Hour Infusions of HNO (Nitroxyl) Donor in Hospitalized Patients With Heart Failure [STANDUP AHF]; NCT03016325).
- 650 _2
- $a akutní nemoc $7 D000208
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 12
- $a srdeční selhání $x farmakoterapie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a oxidy dusíku $7 D009589
- 650 _2
- $a tepový objem $7 D013318
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a funkce levé komory srdeční $7 D016277
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a McMurray, John J V $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
- 700 1_
- $a Cleland, John G $u Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom and National Heart & Lung Institute Imperial College, London, United Kingdom
- 700 1_
- $a O'Connor, Christopher M $u Inova Heart and Vascular Institute, Falls Church, Virginia, USA
- 700 1_
- $a Teerlink, John R $u Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine, University of California San Francisco, San Francisco, California, USA
- 700 1_
- $a Voors, Adriaan A $u University of Groningen, Department of Cardiology, University Medical Center Groningen, Groningen, the Netherlands
- 700 1_
- $a Belohlavek, Jan $u 2nd Department of Internal Medicine, Cardiovascular Medicine, General University Hospital, Charles University in Prague, Czech Republic
- 700 1_
- $a Böhm, Michael $u Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg/Saar, Germany
- 700 1_
- $a Borentain, Maria $u Bristol-Myers-Squibb, Princeton, New Jersey, USA
- 700 1_
- $a Bueno, Hector $u Cardiology Department, Hospital Universitario 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain
- 700 1_
- $a Cole, Robert T $u Inova Heart and Vascular Institute, Falls Church, Virginia, USA
- 700 1_
- $a DeSouza, Mary M $u Bristol-Myers-Squibb, Princeton, New Jersey, USA
- 700 1_
- $a Ezekowitz, Justin A $u Canadian VIGOUR Centre at the University of Alberta, Edmonton, Alberta, Canada
- 700 1_
- $a Filippatos, Gerasimos $u National and Kapodisrian University of Athens, School of Medicine, Athens, Greece
- 700 1_
- $a Lang, Ninian N $u British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom
- 700 1_
- $a Kessler, Paul D $u Bristol-Myers-Squibb, Princeton, New Jersey, USA
- 700 1_
- $a Martinez, Felipe A $u Instituto DAMIC, Cordoba National University Cordoba, Argentina
- 700 1_
- $a Mebazaa, Alex $u Department of Anaesthesiology and Critical Care Medicine, Saint Louis Lariboisière University Hospitals, Assistance Publique - Hôpitaux de Paris, Université de Paris, Inserm 942-MASCOT, FHU PROMICE, Paris, France
- 700 1_
- $a Metra, Marco $u Institute of Cardiology, ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
- 700 1_
- $a Mosterd, Arend $u Department of Cardiology, Meander Medical Center, Amersfoort, the Netherlands and Dutch Network for Cardiovascular Research, Utrecht, the Netherlands
- 700 1_
- $a Pang, Peter S $u Indiana University School of Medicine, Indianapolis, Indiana, USA
- 700 1_
- $a Ponikowski, Piotr $u Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Sato, Naoki $u Cardiology and Intensive Care Unit, Nippon Medical School, Musashi-Kosugi Hospital, Kawasaki, Japan
- 700 1_
- $a Seiffert, Dietmar $u Bristol-Myers-Squibb, Princeton, New Jersey, USA
- 700 1_
- $a Ye, June $u Bristol-Myers-Squibb, Princeton, New Jersey, USA
- 773 0_
- $w MED00184931 $t JACC. Heart failure $x 2213-1787 $g Roč. 9, č. 2 (2021), s. 146-157
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33248986 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133205 $b ABA008
- 999 __
- $a ok $b bmc $g 1714991 $s 1146644
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 9 $c 2 $d 146-157 $e 20201125 $i 2213-1787 $m JACC. Heart failure $n JACC Heart Fail $x MED00184931
- LZP __
- $a Pubmed-20211013
